Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(4.23)
# 528
Out of 4,413 analysts
76
Total ratings
48.39%
Success rate
16.74%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $11.21 | +33.81% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $1.93 | +314.51% | 7 | Mar 11, 2024 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Hold | $25 | $17.05 | +46.63% | 15 | Dec 14, 2023 | |
| IMVT Immunovant | Initiates: Buy | $50 | $28.52 | +75.32% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $143.03 | -4.92% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $8.48 | +88.68% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $21.42 | +189.45% | 5 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $5.28 | +127.27% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $13.28 | +58.13% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $130.90 | -16.73% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $3.25 | +146.15% | 1 | Dec 12, 2023 | |
| LBPH Longboard Pharmaceuticals | Maintains: Buy | $24 → $17 | $21.96 | -22.59% | 3 | Mar 9, 2023 | |
| ATAI Atai Life Sciences | Maintains: Buy | $20 → $10 | $2.05 | +387.80% | 4 | Jan 9, 2023 | |
| PASG Passage Bio | Maintains: Buy | $7 → $5 | $1.35 | +270.37% | 2 | Nov 11, 2022 | |
| KOD Kodiak Sciences | Downgrades: Sell | $6 | $3.53 | +69.97% | 4 | Aug 2, 2022 | |
| DRTS Alpha Tau Medical | Initiates: Buy | $21 | $2.43 | +764.20% | 1 | Apr 4, 2022 | |
| INSM Insmed | Initiates: Outperform | n/a | $25.59 | - | 1 | Jul 11, 2017 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $26.02 | - | 1 | Jul 11, 2017 |
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $11.21
Upside: +33.81%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $1.93
Upside: +314.51%
ACADIA Pharmaceuticals
Dec 14, 2023
Downgrades: Hold
Price Target: $25
Current: $17.05
Upside: +46.63%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $28.52
Upside: +75.32%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $143.03
Upside: -4.92%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $8.48
Upside: +88.68%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $21.42
Upside: +189.45%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $5.28
Upside: +127.27%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $13.28
Upside: +58.13%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $130.90
Upside: -16.73%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $3.25
Upside: +146.15%
Longboard Pharmaceuticals
Mar 9, 2023
Maintains: Buy
Price Target: $24 → $17
Current: $21.96
Upside: -22.59%
Atai Life Sciences
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $2.05
Upside: +387.80%
Passage Bio
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $1.35
Upside: +270.37%
Kodiak Sciences
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $3.53
Upside: +69.97%
Alpha Tau Medical
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $2.43
Upside: +764.20%
Insmed
Jul 11, 2017
Initiates: Outperform
Price Target: n/a
Current: $25.59
Upside: -
AnaptysBio
Jul 11, 2017
Initiates: Outperform
Price Target: n/a
Current: $26.02
Upside: -